Los Angeles, Oct. 08, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (OTCQB:BICX), developer of the BioCorRx® Recovery Program, a Medication-Assisted Treatment (MAT) program, announces a new distribution agreement with an existing wellness center in the Atlanta area. The agreement is part of the Company’s continued focus to distribute its addiction treatment program specific to long-lasting Naltrexone therapy to wellness centers nationally through a partnership with Myriad Medical Marketing (MMM). The new center, Superior Health Care LLC, is run by Dr. Steve Peyroux and is located at 2050 Cumming Way, #100 Canton, GA 30115.
“The availability of our newly rebranded program, the BioCorRx® Recovery Program, in this new clinical setting in the heavily populated Southeast is great news for those suffering from addiction in that area of the country. These individuals will soon have access to the benefits of our program in an environment that offers many other services that can be beneficial to them during their recovery,” says BioCorRx COO & interim CEO, Brady Granier.
Recent Interviews
BioCorRx Inc., (OTCQB: BICX) COO and interim CEO Brady Granier was recently interviewed by Stu Taylor, who broadcasts on the Money Matters and Biz Talk Radio Networks. Mr. Taylor opened his show by discussing the Company then deferring to Mr. Granier, who outlined the scope of addiction in the United States, namely, depending on the research, 18 million or more alcoholics and millions more drug addicts. The cost and collateral damage of alcoholism alone is over 200 billion annually. That number does not address the opioid market, which is growing steadily worse. Mr. Granier continued in speaking about the BioCorRx Recovery Program, (also known as the Start Fresh Program), which provides Medication-Assisted Treatment (MAT) using a surgically implanted form of the FDA approved drug naltrexone. The implant works by reducing cravings for opioids and alcohol for several months while the patient undergoes the second part of the BioCorRx Recovery Program, which involves outpatient counseling. MAT has recently been endorsed as effective by the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute of Alcohol Abuse and Alcoholism (NIAAA). Mr. Granier went on to address how BioCorRx’s program is providing newer treatment options as methods of addiction treatment are changing. Mr. Granier also recently attended the Singular Research Best of the Uncovereds Conference on behalf of the BioCorRx Recovery Program.
Listen here for the full interview with Stu Taylor
Visit BioCorRx, Inc.’s investor relations website www.BICXcorp.com to receive more company information.
Click here to view the BioCorRx YouTube Channel
About BioCorRx
BioCorRx, Inc. ® (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program (also known as the Start Fresh Program®), a Medication-assisted Treatment (MAT) program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.